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HepatocytesLow-density lipoprotein receptor (LDLR) mediates hepatic clearance of plasma cholesterol; propro-
tein convertase subtilisin/kexin 9 (PCSK9) opposes this clearance by promoting LDLR degradation.
The plant ﬂavonoid quercetin-3-b-D-glucoside (Q3G) has been shown to reduce hypercholesterol-
emia in experimental animals. Here, we examined how it affects LDLR and PCSK9 expression as well
as LDL uptake by human Huh7 hepatocytes. At low micromolar concentrations, Q3G increased LDLR
expression, reduced PCSK9 secretion, and stimulated LDL uptake. It also diminished intracellular
sortilin, a sorting receptor known to facilitate PCSK9 secretion. Thus, as an LDLR inducer and a
PCSK9 anti-secretagogue, Q3G may represent an effective anti-cholesterolemic agent.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Elevated circulating low-density lipoprotein-cholesterol (LDL-
C) is a risk factor for cardiovascular disease [1]. Clearance of plasma
LDL-C is primarily mediated by hepatic LDL receptors (LDLR) [2].
This clearance is opposed by proprotein convertase subtilisin/kexin
type 9 (PCSK9) [3], a member of the proprotein convertase family
of endoproteinases known to activate precursor proteins in the
secretory pathway [4,5]. In human hepatocytes, PCSK9 is biosyn-
thesized in the endoplasmic reticulum (ER) as a 72-kDa proPCSK9.
For this zymogen to exit the ER, it must undergo autocatalyticcleavage after the prodomain, generating a 14-kDa propeptide
and a glycosylated 63-kDa mature enzyme. The two moieties form
a stable, non-covalent, and enzymatically inactive complex which
is secreted into circulation [6,7]. This complex binds to LDLR at
the surface of hepatocytes, gets endocytosed with it and, prevent-
ing its return to the cell surface, reroutes it into lysosomes where it
is degraded [8]. PCSK9-mediated LDLR degradation reduces LDL-C
clearance. These observations provided a mechanism for the
hypercholesterolemia associated with certain PCSK9 genetic muta-
tions [9–11].
Hypercholesterolemia is commonly treated with statins, a class
of drugs that inhibit cholesterol biosynthesis by inactivating 3-
hydroxy-3-methylglutaryl-CoA reductase (HMG-CoAR), the rate-
limiting enzyme in this process [12]. Because they reduce intracel-
lular cholesterol, statins induce feedback up-regulation of nuclear
sterol regulatory element-binding protein 2 (SREBP-2), the tran-
scription factor that drives cholesterol biosynthesis. This factor
also activates transcription of the LDLR and PCSK9 genes [13]. The
coordinated up-regulation of these two functionally opposing
genes limits the therapeutic efﬁcacy of statins. Consistently,
induced or genetic deﬁciency of PCSK9 expression or activity has
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Furthermore, results from clinical trials indicate that PCSK9
inhibitors represent a novel class of statin-potentiating agents
[17–19].
Many plant parts contain compounds with anti-cholesterolemic
properties [20]. Quercetin appears to be one such phytochemical
[21]. Found in a broad range of fruits and vegetables, predomi-
nantly as quercetin-3-O-b-D-glucoside (Q3G) [22] (Fig. 1A), this
bioﬂavonoid has been shown to reduce diet-induced hyperlipid-
emia and atherosclerosis in rabbits [23,24] and to attenuate meta-
bolic syndrome in obese Zucker rats [25]. In this study, we
examined how Q3G affects LDLR and PCSK9 expression in human
Huh7 hepatocytes.
2. Materials and methods
2.1. Materials
Huh7 human liver cells were obtained from the Japanese Collec-
tion of Research Bioresources. The rabbit anti-human PCSK9 anti-
body used for immunoblotting was obtained from Dr. Nabil G.
Seidah (Clinical Research Institute of Montreal). The rabbit anti-
human PCSK9 antibody for immunoprecipitation was produced
in house. The following antibodies were from commercial sources:
anti-human LDLR (R&D Systems), anti-b-actin (Sigma), anti-SREBP-
2 (Santa Cruz), anti-HMG-CoAR (Millipore), and anti-sortilin
(Abcam), Horseradish peroxidase (HRP)-conjugated anti-rabbit or
mouse immunoglobulins (Ig) (GE HealthCare) or anti-goat Ig (Santa
Cruz). The chemiluminescence revelation kit was from PerkinEl-
mer; the PCSK9 ELISA kit from Circulex; the RNeasy extraction
kit from Qiagen; the Superscript II RNase H– Reverse Transcriptase,
bodipy-LDL, non-conjugated LDL and Alexa Fluor 488™ were fromFig. 1. (A) Structure of Q3G. (B–C) Q3G effects on the levels of LDLR and PCSK9 expression
Q3G. Levels of mRNA were determined by qRT-PCR (B); those of proteins by sq-immuno
experiments ± and standard errors of means (SEM). They are expressed relative to untr
letters above symbols of means ± SEM. PCSK9 preﬁxes ic- and sec- stand for intracellula
glycosylated mature form of the receptor. A co-regulated immature form can be observInvitrogen; lipoprotein-depleted serum (LPDS), Q3G and simvasta-
tin from Sigma; the FastStart TaqMan ProbeMaster-Rox master
mix, primer pairs, and Universal Probe Library (UPL) ﬂuorescent
probes, and the Protease Inhibitor Cocktail (PIC) from Roche; the
Amplify ﬂuor solution from Amersham Biosciences, the Vecta-
shield mounting medium with 40,6-diamidino-2-phenylindole
(DAPI) from Vector Laboratories.
2.2. Cell culture and lysis
Unless otherwise speciﬁed, all Huh7 cell incubations were car-
ried out at 37 C in a humidiﬁed 5% CO2–95% air atmosphere. At
passage, cells were seeded at sub-conﬂuence (106 cells/3.5-cm
dish) in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS) for maintenance or LPDS for experi-
ments, and 50 lg/ml gentamycin; they were incubated overnight
and then treated or not with Q3G, or simvastatin, or both, at
deﬁned concentrations, and for deﬁned lengths of time; media
were collected, centrifuged at 200g for 5 min to sediment sus-
pended cells, and collected supernatants were supplemented 0.02
volumes of a 50 stock PIC; cell monolayers were rinsed with
ice-cold phosphate-buffered saline (PBS), overlaid with 0.5 ml of
the RIPA lysis buffer (50 mM Tris–HCl, pH 8, 150 mM NaCl, 1%
NP-40, 0.5% Na-deoxycholate and 0.1% SDS) supplemented with
1 PIC, and placed on an ice bath for 20 min; lysates were centri-
fuged at 14,000g and 4 C for 20 min, and supernatants collected.
Spent media and cell lysates were stored at 20 C until analysis.
2.3. Metabolic labeling
Huh7 cells were seeded onto 12-well plates at 8  105 cells/well
in 1.5 ml/well of complete medium and incubated overnight; afterCells were incubated for 24 h in medium containing the indicated concentrations of
blotting in cell extracts or ELISA in spent media (C). Values are means of triplicate
eated cells. Signiﬁcant difference (P < 0.05) is represented in the graph by different
r and secreted, respectively. Note that the LDLR band shown in B, a represents the
ed below on overexposed X-ray ﬁlms (not shown).
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of DMEM/10% LPDS without or with 5 lM Q3G, and re-incubated
for 24 h; Met/Cys-depleted serum-free DMEM (SFM, 1.5 ml) was
substituted, and incubation resumed for 20 min to use up endoge-
nous Met and Cys; this medium was removed, fresh SFM (0.75 ml/
well) containing 300 lCi/ml 35S-Met/Cys was added in its place,
and incubation was carried on for another 20 min to label de novo
biosynthesized proteins (pulse-labeling); the radioactive medium
was replaced with DMEM/0.5% LPDS containing 10 mM non-radio-
active Met/Cys and, incubation reinstated for 0, 15, 30, 60, 90 and
120 min (chase); conditioned media were collected and supple-
mented with 0.33 volumes of 3 RIPA lysis buffer containing
30 mM Met/Cys; cells were lysed in 0.5 ml of a 3-fold dilution of
this same buffer.
2.4. Indirect immunoﬂuorescence ﬂow cytometry
Cells were seeded in 6-well plates, at 106 cells/well in 3 ml of
complete medium and incubated overnight; LPDS medium con-
taining or not 5 lM Q3G was substituted and incubation resumed
for 24 h; after two rinses with PBS-D, cell monolayers were over-
laid with 2 ml of Versene and incubated for 20 min; detached cells
were suspended and their concentration determined using an
hemocytometer; they were sedimented by a 5-min centrifugation
and suspended in 0.5 ml of DMEM containing 5% bovine serum
albumin (DMEM-5% BSA); 2  106 cells were transferred into an
Eppendorf tube and rinsed 3 times as above; using ice-cold solu-
tions and, keeping them at 4 C to the end of the protocol, they
were suspended in 0.2 ml of DMEM-5% BSA containing 10 lg/ml
of goat antibody against human LDLR and mixed by rotation for
1 h; after 3 rinses with DMEM-5% BSA, they were suspending in
0.2 ml of the same buffer supplemented with Alexa Fluor-488-con-
jugated donkey antibody against goat immunoglobulins, and
mixed for another 1 h; after 3 other rinses with DMEM-5% BSA,
they were suspended in PBS-D and analyzed in a Benson–Dicken-
son XL 488 Laser ﬂow cytometer. Cell autoﬂuorescence and non-
speciﬁc ﬂuorescence were assessed using cells not treated with
the secondary and the primary antibody, respectively.
2.5. Confocal microscopy
Huh7 cells were seeded in 4-well chamber slides at 2.4  105 -
cells/well and grown for 24 h; LPDS medium containing or not
5 lM Q3G was substituted and incubation resumed for 24 h; kept
at room temperature to the end of the protocol, cells were ﬁxed
with 1% paraformaldehyde in PBS for 15 min; they were treated
for indirect immunoﬂuorescence as for ﬂow cytometry, except that
PBS was substituted for DMEM in the various solutions; they were
mounted on the Vectashield mounting medium containing 40,6-
diamidino-2-phenylindole (DAPI); confocal images were captured
with an Olympus 1X70 inverted microscope equipped with a Bio-
Rad MRC-1024 confocal laser-scanning unit at 488 nm and
522 nm excitation and emission wavelengths, respectively, using
an Olympus UApo 40_ (NA 1.15) water immersion lens. Sections
were taken every 50 lm (Z-series) through the thickness of the
cells.
2.6. LDL uptake assay
Huh7 cells were seeded in 96-well black-bottom plates at
4  104 cells/well in 0.1 ml complete medium and allowed to
attach by overnight incubation; they were then rinsed with PBS-
D, overlaid with 0.1 ml of DMEM/10% LPDS and incubated for
24 h; after a PBS-D rinse, they were overlaid with 0.1 ml DMEM/
0.5% LPDS containing or not 5 lM Q3G and incubated for 24 h. To
assay for LDL uptake, cells were rinsed, ﬁrst with pre-warmed(37 C) PBS-D, then with pre-warmed DMEM/0.5% LPDS; they were
overlaid with 75 ll of the latter medium containing 20 lg/ml bod-
ipy-LDL, and then incubated at 37 C for 15 min or 30 min to allow
LDLR-mediated endocytosis of the ﬂuorescent lipoprotein; the pro-
cess was stopped by substituting ice-cold DMEM/0.5% LPDS; after 3
rinses with 0.2 ml of ice-cold PBS-D, the cells were ﬁxed with
0.1 ml of isopropanol for 20 min, in the dark, with gentle shaking;
intracellular ﬂuorescence was measured in a SpectraMax Gemini
XS ﬂuorescence plate reader (Molecular Devices) at the excitation
and emission wavelengths of 485 and 535 nm, respectively. Non-
speciﬁc ﬂuorescence was measured by incubating cells in medium
containing bodipy-LDL (20 lg/ml) and a 12.5 excess of non-ﬂuo-
rescent LDL (250 lg/ml).
2.7. RT-qPCR
Total RNA was extracted using the Qiagen RNeasy extraction
kit. It was reverse-transcribed into cDNA using oligo-dT primers
and the Superscript II RNase H– Reverse Transcriptase. The levels
of speciﬁc cDNAs were quantiﬁed by PCR-based ﬂuorogenic Taq-
man assays, using FastStart TaqMan ProbeMaster-Rox master
mix, primer pairs and the appropriate ﬂuorescent UPL probes
(Table 1), in a Mx3005P thermocycler (Stratagene). Standard
curves were established using varying amounts of puriﬁed and
quantiﬁed cDNA amplicons of each mRNA. The level of mRNA for
the TATA-binding protein (TBP) was used for normalization.
2.8. Immunoblotting
Cell lysates were fractionated by SDS–PAGE and electrophoret-
ically transferred onto a polyvinylidene ﬂuoride membrane. The
membrane was incubated with a goat anti-human LDLR, rabbit
anti-PCSK9, rabbit anti-SREBP-2 polyclonal antibody, rabbit anti
HMG-CoAR, or rabbit anti-sortilin at 1:1000, 1:1500, 1:200,
1:2000, or 1:2000 dilutions, respectively, and then with a HRP-con-
jugated heterospeciﬁc secondary antibody against the primary Igs
at a 1:5000 and 1:10,000 dilution for goat and rabbit or mouse
antibody, respectively. It was probed for HRP reaction using the
Western Lightning Chemiluminescence Reagent Plus a chemilumi-
nescence-based revelation kit. The signal was captured on X-ray
ﬁlm and immunoreactive bands analyzed by densitometry on a
Syngene’s ChemiGenius2XE Bio Imaging System within the
dynamic range of the instrument. The membrane was stripped
and reprobed with the anti-b-actin monoclonal primary antibody
at 1:20,000 dilution and HRP-conjugated rabbit anti-mouse IgG
secondary antibody at a 1:10,000 dilution. The densitometric val-
ues of b-actin bands were using for normalization of experimental
samples.
2.9. Immunoprecipitation
Radioactive conditioned media or cell lysates (0.1 ml) were sup-
plemented with 0.2 ll of normal rabbit serum and 15 ll of a 50%
(w/v) suspension of Protein A-agarose. After a 1-h incubation at
4 C with rotational mixing, the samples were centrifuged at
3000g for 5 min at 4 C. Supernatants were supplemented 2 ll of
rabbit anti-PCSK9, and incubated as above. The resin with bound
immune complexes was then sedimented by centrifugation as
above, rinsed three times with RIPA buffer, twice with a buffer con-
taining 1 M NaCl, 10 mM Tris–HCl and 1 mM EDTA, pH 8, and twice
with PBS containing 1 mM EDTA. Pellets were suspended each in
25 ll of 2x Tricine-DTT sample buffer (100 mM Tris–HCl, pH 6.8,
24% glycerol, 8% SDS, 5% b-mercaptoethanol, 50 mM DTT, and
0.02% bromophenol blue), boiled for 5 min, and sedimented as
above. Supernatant was subjected to electrophoresis through
Tris-Tricine polyacrylamide gels (8% or 12%). Gels were ﬁxed for
Table 1
UPL primers and probes.a
Gene Exon number: Primer sequence Amplicon
Forward Reverse Size (bp) Probe #
HMGCOAR Exon 14: gggatgaacatgatttcaaagg Exon 15: ttttcctcttccctctatccaa 147 62
LDLR Exon 17: aggacggctacagctaccc Exon18: ctccaggcagatgttcacg 73 88
PCSK9 Exon 2: catgtcttccatggccttct Exon3: tagtcgacatggggcaactt 89 62
SORTILIN Exon 9: gcagcaaatgatgacatggt Exon 10: gaggtaaagattgtgccaaacc 74 80
SREBP2 Exon 2: gcctttgatataccagaatgcag Exon 3: cctgctgctgaatggtgac 107 88
TBP Exon 2: gaacatcatggatcagaacaaca Exon 3: atagggattccgggagtcat 87 87
a The probes were designed using an online algorithm at the Roche Universal Probe Library Assay Design Center (www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp).
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30 min with Amplify ﬂuor solution, dried under vacuum and
exposed to phosphorimaging screen overnight. Speciﬁc radioactive
protein bands were visualized and quantiﬁed on a Typhoon Phos-
phorimager (Molecular Dynamics).
2.10. ELISA
PCSK9 levels in conditioned media were measured using a
human PCSK9-speciﬁc sandwich ELISA kit, as speciﬁed by the
manufacturer.
2.11. Statistical analysis
All experiments were repeated at least twice and in triplicates.
Values are expressed as means ± standards errors of means (SEM).
Signiﬁcance of differences among several experimental conditions
was evaluated by ANOVA, between two conditions by Student’s t
test, using the GraphPad Prism 5 software.
3. Results
3.1. Q3G increased LDLR expression and reduced PCSK9 secretion
Huh7 cells were incubated for 24 h in medium containing 0–
10 lM Q3G. The level of LDLR and PCSK9 mRNA was measured
by qRT-PCR. The treatment increased LDLR mRNA levels in a con-
centration-dependent manner, by a maximum 60% at 2 lM
(P < 0.01); in contrast, starting at 4 lM, it reduced PCSK9 mRNA
levels by 20–30% (P < 0.05) (Fig. 1B).
The levels of corresponding proteins in cell extracts and cell
media were evaluated by sq-immunoblotting and ELISA, respec-
tively. The treatment remarkably increased total LDLR levels start-
ing at 2 lM (by 300–400%; P < 0.005); interestingly, starting at
4 lM, it gradually increased intracellular PCSK9 levels (by 20–
90%; P < 0.05), while reducing its levels in spent media (by 30–
35%; P < 0.05) (Fig. 1C).
Time course immunoblotting analysis of extracts of cells treated
with 2 lM Q3G for 0.5–48 h revealed that cellular accumulation of
PCSK9 and LDLR begun after a 3-h and a 6-h lag, respectively; it
reached a maximum after 27 h for both (not shown).
3.2. Q3G increases nuclear SREBP-2 and delays PCSK9 secretion
The increase in LDLR mRNA content could be attributed to up-
regulation of its gene transcription by SREBP-2 [26], a nuclear fac-
tor generated through two successive cleavages of its ER mem-
brane-bound precursor form by the Golgi proteases S1P and S2P
[27]. The effect of Q3G on SREBP-2 expression was therefore exam-
ined. The ﬂavonoid had no effect on the level of SREBP-2 mRNA
(Fig. 2A, a), but, starting at 4 lM, it increased that of HMGCoAR
(Fig. 2A, b; P < 0.05) and decreased that ATP-binding cassette trans-porter A1 (ABCA1) (Fig. 2A, c; P < 0.01), two proteins implicated in
cholesterol homeostasis and whose gene transcription is regulated
by SREBP-2, positively for the former [26] and negatively for the
latter [28].
Increased SREBP-2 activity, as suggested by the regulation of
HMGCoAR and ABCA1 mRNA levels, could have resulted from
greater post-translational conversion of the inactive 148-kDa ER
precursor of SREBP-2 to its active 65-kDa nuclear form. Indeed,
immunoblotting analysis of these proteins showed that, starting
at 2 lM, Q3G stimulated this conversion 2–4-fold (Fig. 2B).
Q3G treatment apparently reduced PCSK9 secretion causing its
intracellular accumulation. Since PCSK9 can be secreted only after
endoproteolytic cleavage of its precursor [6,7], the possibility of
impaired proPCSK9 maturation was examined after radioactively
pulse labeling it during biosynthesis. As shown in Fig. 2C, chase
of untreated and treated cells revealed a gradual intracellular con-
version of proPCSK9 to mature PCSK9 (upper panel), associated
with a gradual appearance of the latter in spent media (lower
panel). No obvious difference in the rate of intracellular precursor
processing was observed. However, when cumulative levels of
secreted PCSK9 were expressed as percentages of total PCSK9 pro-
teins (precursor PCSK9 and mature PCSK9 in cells and media), they
were found to be consistently lower in spent media of Q3G-treated
cells, relative to those of untreated cells, most noticeably at early
chase time points (lower panel), suggesting delayed secretion.
It has been suggested that PCSK9 transport in the secretory
pathway is facilitated by active packaging into SEC24A-coated ves-
icles at the ER-cis Golgi interface and by the sorting receptor sorti-
lin in the trans-Golgi network (TGN), since knockdown or knockout
of expression of either protein is associated with reduced PCSK9
secretion and its overexpression with stimulation of this secretion
[29,30]. We therefore examined whether down regulation of
PCSK9 secretion in Q3G-treated cells could be associated with
diminished expression of these proteins. Treatment of Huh7 cells
with 5 mM Q3G for 24 h reduced the intracellular level of sortilin
by about 50% (P < 0.001) (Fig. 3A), and that of its mRNA by about
40% (P < 0.01) (Fig. 3B). It induced no change in Sec24A content
(not shown). These observations suggested that PCSK9 retention
in Q3G-treated Huh7 cells might be partly due to induced sortilin
deﬁciency.
3.3. Q3G increased cell surface expression of LDLR and accelerated LDL
uptake
To be functionally relevant, Q3G-induced LDLR must reach the
cell surface where it could mediate LDL uptake. We stained cells
at 4 C for surface LDLR by indirect immunoﬂuorescence and
assessed its level by ﬂow cytometry. Pretreatment with 5 lM
Q3G increased cell surface LDLR 1.7-fold (Fig. 4A; P < 0.001), sug-
gesting that it rendered the cells more capable of taking up more
exogenous LDL. This prediction was veriﬁed using a ﬂuorescent
LDL uptake assay. Compared to untreated cells, cells pretreated
Fig. 2. Q3G stimulates nuclear SREBP-2 production and delays PCSK9 secretion. Cells were incubated for 24 h in medium containing the indicated concentrations of Q3G. (A)
qRT-PCR for mRNA levels of SREBP-2, HMGCoAR and ABCA1. Values are means of triplicate experiments ± SEM. They are expressed relative to untreated cells. Signiﬁcant
difference (P < 0.05) is represented in the graph by different letters above symbols of means ± SEM. (B) Sq-immunoblotting for cellular SREBP-2-related proteins. Density
ratios of the 65-kDa SREBP over the 148-kDa precursor SREBP after normalization for b-actin were derived from two separate experiments. (C) Cells were pre-incubated for
24 h in medium 5 lM Q3G. After metabolic labeling with radioactive amino acids, labeled proteins were chased in Q3G-free non-radioactive medium, for varying lengths of
time. PCSK9-related proteins were immunoprecipitated, fractionated by SDS–PAGE, and quantiﬁed by phosphorimaging. Upper panel: PCSK9-related proteins in cell lysates.
Lower panel: PCSK9-related proteins in spent media. The percents of secreted PCSK9 were based on densitometric values of intracellular and extracellular bands
corresponding to proPCSK9 and PCSK9. Asterisks (⁄) indicate possible products of further PCSK9 processing.
Fig. 3. Q3G inhibit sortilin expression. Cells were pre-treated or not with 5 lMQ5G
for 24 h. Their content in sortilin protein was evaluated by sq-immunoblotting (A);
that of sortilin mRNA by qRT-PCR (B). Values are expressed relative to untreated
cells. They represent means of triplicate experiments ± SEM. ⁄⁄⁄P < 0.001; ⁄⁄P < 0.01
by Student t test.
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after 15 min and 30 min, respectively (Fig. 4B, P < 0.005).
3.4. Q3G potentiates statin-induced LDLR increase but not PCSK9
secretion
Statins increase LDLR expression as well as PCSK9 secretion
[13,31,32]. Q3G, as this study indicated, stimulate LDLR expression
while reducing PCSK9 expression and secretion. An experiment
was conducted to determine whether, at an optimum concentra-
tion of Q3G (5 lM), simvastatin at 0.2 and 1 lM could further up
regulate LDLR expression; and, inversely, whether the bioﬂavonoidcan reduce statin-stimulated PCSK9 secretion. As shown in Fig. 5.
In the absence of Q3G (open bars), simvastatin treatment, in a con-
centration-dependent manner, increased the levels of cellular LDLR
(Fig. 5A.a), cellular PCSK9 (Fig. 5A.b), and secreted PCSK9 (Fig. 5B).
Co-treatment with 5 lM Q3G (black bars), increased cellular LDLR
to the level induced by the bioﬂavonoid alone (Fig. 5A.a); it further
increased the amount of cellular PCSK9 (Fig. 5A.b), while maintain-
ing or slightly reducing its level in spent media (Fig. 5B). Thus,
while both simvastatin and Q3G stimulated LDLR expression;
Q3G could additionally reduce PCSK9 secretion.
4. Discussion
Data presented in this report indicate that, at low micromolar
concentrations, Q3G accelerates hepatocyte uptake of exogenous
LDL by increasing expression and cell surface localization of LDLR.
The increased expression of the receptor could be partly explained
by transcriptional activation of its gene following stimulated con-
version of the ER precursor form of SREBP-2 to its nuclear active
form. This conversion is known to be promoted by a deﬁcit of free
cholesterol in the ER [27]. It is possible that, like red grape juice
polyphenols [33], Q3G causes such a deﬁcit by delaying the trans-
port of endocytosed LDL and its breakdown components from
endosomes, through lysosomes, into the cytoplasm.
The PCSK9 promoter also carries a sterol-regulatory element
responsive to activation by nuclear SREBP-2 [13]. But its sustained
activation by this factor strongly depends on the presence of co-
activators including of hepatocyte nuclear factor 1a (HNF-1a)
[34,35] and histone nuclear factor P (HINFP) [36]. Reduced expres-
sion of either factor has been shown to repress PCSK9 gene tran-
scription. We found that Q3G does not alter HNF1a expression in
Huh7 cells (not shown). Its effect of HINFP expression remains to
be veriﬁed.
Fig. 4. Q3G increases cell surface LDLR and LDL uptake. Cells were pre-treated or not with 5 lM Q5G; (A) they were then stained for LDLR indirect immunoﬂuorescence and
analyzed by (a) ﬂow cytometry, or (b) confocal microscopy, (c) means of ﬂuorescence ± SEM were compared. The experiment was conducted in triplicates. (B) Cells were
incubated bodipy-LDL for up to 30 min; uptake of the lipoprotein was measured by ﬂuorescence spectrometry. Values represents means of 6 replicates ± SEM. ⁄⁄⁄P < 0.005;
⁄⁄P < 0.01 by Student t test.
Fig. 5. Q3G reduces statin-induced PCSK9 secretion. Cells were incubated for 24 h in culture medium containing 5% FBS and simvastatin (SMV: 0, 0.2, or 1 lM), without or
with 5 lMQ3G. The levels of LDLR and PCSK9 in cell extracts were evaluated by sq-immunoblotting; that of PCSK9 in spent media by ELISA. Signiﬁcant difference (P < 0.05) is
represented in the graph by different letters above symbols of means ± SEM.
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unclear. The retention was not caused by impaired autoproteolytic
processing of its precursor, a prerequisite for its exit from the ER
[7] as a cargo in COPII-coated vesicles. The presence of SEC24A in
the COPII complex is necessary for the efﬁciency of this exit [29].
Our analysis indicated that SEC24A expression is not affected byQ3G. In the TGN, PCSK9 packaging into secretory vesicles is facili-
tated by the protein sorting receptor sortilin [30]. Here we report
that treatment of Huh7 hepatocytes Q3G signiﬁcantly inhibits
sortilin expression at the mRNA and protein levels. This inhibi-
tion could partly explain the intracellular retention of PCSK9.
Interestingly, quercetin is also known to reduced secretion of
M. Mbikay et al. / FEBS Open Bio 4 (2014) 755–762 761apolipoprotein B (ApoB) [37], the major protein component of LDL
particles. ApoB, like PCSK9, depends on sortilin for efﬁcient secre-
tion [38,30]. If Q3G can inhibit sortilin expression in vivo, it could
reduce the negative impact of PCSK9 secretion on the half-life of
hepatic LDLR and thus promote plasma LDL-C clearance. An LDL-
C-reducing effect of sortilin deﬁciency has been reported in mice
[39,30]. However, other mouse studies have observed the opposite,
i.e. lower plasma LDL-C was caused by sortilin overexpression
[40,41]. These discrepancies may be due to differences of induced
modiﬁcations in the experimental mice which may have differen-
tially affected the ability of sortilin to target its ligands towards
either secretion (ApoB, PCSK9) or intracellular degradation in lyso-
somes (LDL, VLDL) [42].
Interestingly, we did not observe any alteration of PCSK9 secre-
tion or LDLR expression in Huh7 cells exposed to quercetin agly-
cone at single-digit micromolar concentrations (data not shown).
LDLR up regulation has reportedly been achieved in HepG2 hepato-
cytes treated with this unmodiﬁed ﬂavonoid at 75 lM [43]. The
greater efﬁciency of Q3G could be explained by its more active
receptor-mediated uptake by cells [44,45]. It should be noted how-
ever that, in vivo, orally administered Q3G is converted to querce-
tin through deglycosylation by hydrolases found in brush border
membrane cells of the small intestine. In enterocytes, quercetin
is largely metabolized to glucuronidated and/or methylated forms
which are released into the bloodstream and taken up by multiple
tissues, including the liver [46,47]. Quercetin uptake and metabo-
lism by hepatocytes ex vivo have been studied [48]. A similar study
for Q3G remains to be conducted.
In conclusion, as an LDLR inducer, a sortilin inhibitor and a
PCSK9 anti-secretagogue, Q3G could make an effective anti-choles-
terol agent.
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